Bar&Bench News Network reported on 05 May, 2010 that Swiss pharma firm, Hoffman-La Roche suffered a major blow with the Chennai Patent Office deciding against its patent relating to anti-viral drug Valcyte. In the post-grant opposition filed by various Indian pharmaceutical companies, the patent controller ruled against Roche stating that Valcyte lacked inventive step.

Roche had developed an ester of a pre-existing intravenous anti-viral drug, Gancyclvoir, administered mostly to HIV patients, called L Valinate. In an attempt to make the drug's consumption easier, mainly through oral administration, Roche developed [...]

OUVRIR MON COMPTE CREATE MY ACCOUNT

  Un problème avec cet article ? / A problem with this article?